

December 8, 2020

British Columbia Securities Commission  
Alberta Securities Commission  
Ontario Securities Commission

Dear Sirs/Mesdames:

We refer to the prospectus of Tryp Therapeutics Inc. (the “Company”) dated December 8, 2020 relating to the Company’s offering of a minimum of 17,400,000 units of the Company at \$0.25 per unit (the “Prospectus”).

We consent to being named and to the use in the Prospectus, of our report dated December 8, 2020 to the shareholders of the Company on the following financial statements:

- Statement of financial position as at August 31, 2020;
- Statement of comprehensive loss, changes in shareholders’ equity and cash flows for the 343-day period ended August 31, 2020, and a summary of significant accounting policies and other explanatory information.

We report that we have read the Prospectus and all information therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor’s consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the Prospectus, as these terms are defined in the Chartered Professional Accountants of Canada Handbook – Assurance.

Yours very truly,

*Smythe LLP*

Chartered Professional Accountants

MSo/map/1001057